MedPath

omega3 PUFA add-on therapy for bipolar disorder: genotype stratified analysis

Phase 2
Conditions
Bipolar disorder
Registration Number
JPRN-jRCTs041180075
Lead Sponsor
Iwata Nakao
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Bipolar Disorder (I and II) diagnosed by DSM-V

Exclusion Criteria

Bipolar disorder (rapid cycling) diagnosed by DSM-V
patients who are taking EPA/DHA
Allergy for EPA DHA
metabolic syndrome at the enrollment
side effect by EPA DHA
high risk of hemorrhage
patients who received more than 3 types of antipsychotics
patients who received more than 3 types of antidepressants (exclude antidepressants which use only as hypnotics)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath